

- 49 -


THE CLAIMS.

1. An isolated Ox receptor in sequencably pure form.
- 5 2. An isolated Ox receptor characterised by a high binding affinity for O501 and a poor binding affinity for methoxyidazoxan, clonidine and idazoxan.
3. An isolated Ox receptor characterised by having a binding affinity for O501 of 1 to 500 nM and affinities for methoxyidazoxan, clonidine and idazoxan of greater than 1000.
- 10 4. A receptor according to claim 3 characterised by having a binding affinity for O501 is between 10 and 100 nM and affinities for methoxyidazoxan, clonidine and idazoxan is greater than 5000 nM.
- 15 5. An isolated nucleic acid molecule which encodes an Ox receptor as claimed in any one of claims 1 to 4.
6. A recombinant plasmid, cosmid, bacteriophage or other recombinant molecule comprising a nucleic acid molecule according to claim 5.
- 20 7. A method for identifying a modulator or Ox receptor activity, said method comprising assaying recombinant Ox receptor activity in the presence of a potential modulator and comparing said activity to the activity of recombinant Ox receptor in the absence of said potential modulator.
- 25 8. A method according to claim 7 wherein the recombinant Ox receptor is obtained by expressing a functional recombinant Ox receptor polypeptide in a cell for a time and under conditions sufficient for said polypeptide to be produced in an assayable quantity.

30

- 50 -

9. Use of a compound of the formula I:



5

where R is the residue of an organic compound, X is O or S and Y is a divalent group making up a 5 or 6 membered ring, which compound has a selectivity for an Ox receptor over one or both of the α_2 - and I₂- receptors of greater than 1, as an agonist or antagonist to the Ox receptor.

10

10. A method for modulating the activity of an Ox receptor including the step of applying to a source of Ox receptor an effective amount of a compound of formula I:




15

where R is the residue of an organic compound, X is O or S and Y is a divalent group making up a 5 or 6 membered ring, which compound has a selectivity for an Ox receptor over one or both of the α_2 - and I₂- receptors of greater than 1.

20

11. A compound having a selectivity for an Ox receptor over one or both of the α_2 - and I₂-receptors of greater than 1, which is a compound of formula II



II

25

wherein W is optionally substituted aryl, optionally substituted C₅-C₇ cycloalkyl or - CHR¹R² where R¹ and R² are independently selected from hydrogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₃-C₇ cycloalkyl, optionally substituted aryl, and OR' where R' is optionally substituted aryl, optionally substituted C₃-C₇ cycloalkyl or

- 51 -

optionally substituted C₁-C₆ alkyl, provided that of R¹ and R² are not both hydrogen, Z is imino, C₁-C₂ alkylene, -CH₂NH- or -CH₂CH₂NH-, X is O or S, and Y is optionally substituted C₂-C₃ alkylene, provided that W is not OR' when Z is imino or -CH₂NH-; and with the further provisos that

- 5 a) when Y is CH₂CH₂, X is O and Z is imino then
- (i) W is not unsubstituted or 2-mono-, 2,2-di, 2,5-di, 2,6-di or 2,4,6-tri C₁₋₃ alkyl substituted cyclohexyl or 2-mono- or 2,5-di C₁₋₃ alkyl substituted cyclopentyl or 2- C₁₋₃ alkyl substituted cycloheptyl; and
 - (ii) if W is CHR¹R² and R¹ is H then R² is not selected from phenyl; phenyl substituted with methoxy, Br, Cl, F or trifluoromethyl; 3-nitrophenyl; 3- or 4-methylphenyl; 2- or 4-bromomethylphenyl; 2- or 4-chloromethylphenyl; or 2,3- or 2,6-dimethylphenyl; and
 - (iii) if W is CHR¹R² and R¹ is CH₃ or cyclopropyl then R¹ is not phenyl or phenyl substituted with alkyl, halomethyl, fluoro or trifluoromethyl; and
- 10 b) when Y is (CH₂)₂₋₄, X is O or S, Z is imino and W is CHR¹R², then
- (i) if R¹ is CF₃, CF₂CF₃ or CF₂CF₂CF₃ then R² is not alkyl, optionally substituted cycloalkyl or optionally substituted aryl, and
 - (ii) if R¹ is optionally substituted cyclopropyl, R² is not H, alkyl or optionally substituted cyclopropyl;
- 20 or a pharmaceutically acceptable ester or salt thereof.

12. A compound of claim 11 wherein W is aryl (optionally substituted with hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, NO₂, NH₂, C₁-C₆ haloalkyl, halogen, C₃-C₆ cycloalkyl, aryl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or aryloxy); C₅-C₆ cycloalkyl (optionally substituted with hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, NO₂, NH₂, C₁-C₆ haloalkyl, halogen, C₃-C₆

- 52 -

cycloalkyl, aryl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or aryloxy); or -CHR¹R² where R¹ and R² are independently selected from hydrogen, C₁-C₆ alkyl (optionally substituted with hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, NO₂, NH₂, C₁-C₆ haloalkyl, halogen, C₃-C₆ cycloalkyl, aryl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or aryloxy), C₃-C₆ cycloalkyl (optionally 5 substituted with hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, NO₂, NH₂, C₁-C₆ haloalkyl, halogen, C₃-C₆ cycloalkyl, aryl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or aryloxy), aryl (optionally substituted with hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, NO₂, NH₂, C₁-C₆ haloalkyl, halogen, C₃-C₆ cycloalkyl, aryl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or aryloxy), and OR' where R' is aryl (optionally substituted with hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, NO₂, NH₂, C₁-C₆ 10 haloalkyl, halogen, C₃-C₆ cycloalkyl, aryl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or aryloxy), C₃-C₆ cycloalkyl (optionally substituted with hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, NO₂, NH₂, C₁-C₆ haloalkyl, halogen, C₃-C₆ cycloalkyl, aryl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or aryloxy), or C₁-C₆ alkyl (optionally substituted with hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, NO₂, NH₂, C₁-C₆ haloalkyl, halogen, C₃-C₆ cycloalkyl, aryl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or aryloxy); 15 provided R¹ and R² are not both hydrogen.

13. A compound of claim 11 or claim 12 where W is phenyl or cyclohexyl, naphthyl, each of which may be optionally substituted with one to three substituents selected from hydroxy, methoxy, ethoxy, benzyloxy, NO₂, NH₂, halogen, methyl and ethyl; or -CHR¹R² 20 where R¹ and R² are independently selected from phenyl, naphthyl, cyclohexyl, cyclopentyl, cyclobutyl, cyclopropyl, methyl, ethyl, propyl and butyl, each of which may be optionally substituted with hydroxy, methoxy, ethoxy, benzyloxy, NO₂, NH₂, halogen, methyl and ethyl, provided R¹ and R² are not both hydrogen.

25 14. A compound of any one of claims 11 to 13 wherein Z is imino or -CH₂CH₂NH-.

15. A compound of any one of claims 11 to 14 wherein X is oxygen.

16. A compound of any one of claims 11 to 15 wherein Y is C₂-C₃ alkylene optionally 30 substituted with C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkanoyloxy or C₁-C₆ alkyloxycarbonyl, or with two substituents which join together to form a 5-6 numbered

- 53 -


carbocyclic or heterocyclic ring.

17. A compound of claim 16 wherein Y is unsubstituted C₂-C₄alkylene.

5 18. A compound of claim 17 wherein Y is ethylene.

19. A compound according to claim 11 which is a compound of formula III:

10




15

wherein R³, R⁴, R⁵ and R⁶ are independently selected from hydrogen, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, NO₂, NH₂, C₁-C₆ haloalkyl, halogen, C₃-C₆ cycloalkyl, aryl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, aryloxy, Z is imino, C₁-C₂ alkylene, or -CH₂CH₂NH-, R⁷ and R⁸ are independently selected from hydrogen, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkanoyloxy or C₁-C₆ alkyloxycarbonyl or R⁷ and R⁸ may together form a 5 or 6 membered aromatic or non-aromatic carbocyclic or heterocyclic ring.

20

20. A compound according to claim 11 which is a compound of formula IV:

25




30 where R³, R⁴, R⁷, R⁸ and Z are as defined in claim 19.

- 54 -

21. A compound according to claim 11 which is a compound of formula V:

5




V

where R^3 , R^4 , R^7 , R^8 and Z are as defined in claim 19, and R^9 is C_1 - C_4 alkyl or C_1 - C_4 alkoxy.

22. A compound according to claim 11 which is a compound of formula VI:

15




VI

where R^7 , R^8 and Z are as defined in claim 19 and R^{10} and R^{11} are independently selected from hydrogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, NO_2 , NH_2 , C_1 - C_6 haloalkyl, halogen, C_3 - C_6 cycloalkyl, aryl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl and aryloxy.

23. A compound according to claim 11 which is a compound of formula VII

25




VII

where R^7 , R^8 and Z are as defined in claim 19 and R^{12} is hydrogen optionally substituted C_1 - C_6 alkyl, optionally substituted C_3 - C_7 cycloalkyl or optionally substituted aryl.

- 55 -

24. A compound according to claim 11 which is a compound of formula VIII:

5




VIII

where ϕ is optionally substituted aryl and R^7 , R^8 and Z are defined in claim 19.

10 25. A compound according to claim 11 which is a compound of formula IX:

15




IX

where R^7 , R^8 and Z and ϕ are as defined in claim 24.

26. A compound according to claim 11 which is a compound of formula X:

20



X

25 where R^7 , R^8 , R^{12} and Z are as defined in claim 23 and ϕ is as defined in claim 24.

27. A compound according to any one of claims 24 to 26 where ϕ is phenyl or naphthyl either of which may have one to four substituents selected from hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, NO_2 , NH_2 , C_1-C_6 haloalkyl, halogen, C_3-C_6 cycloalkyl, aryl, C_2-C_6 alkenyl, C_2-C_6 alkynyl and aryloxy.


- 56 -

28. A compound according to any one of claims 11 to 27 having a selectivity of greater than 3 over one or both of α_2 - and I_2 - receptors.
29. A compound according to any one of claims 11 to 28 having a selectivity for the 5 Ox receptor over both the α_2 - and I_2 - receptors of greater than 1.
30. A compound according to any one of claims 11 to 29 having a selectivity for the Ox receptor over the I_1 receptor of greater than 1.
- 10 31. A compound according to any one of claims 11 to 30 when used to bind to and/or modulate the activity of an Ox receptor.
32. A compound of any one of claims 11 to 30 which is an agonist of Ox receptor activity.
- 15 33. A compound of any one of claims 11 to 30 which is an antagonist of Ox receptor activity.
34. A modulator of Ox receptor activity which is a compound of any one of claims 11 20 to 30.
35. Use of a compound of any one of claims 11 to 30 to bind to and/or modulate the activity of Ox receptor.
- 25 36. A composition comprising a compound according to any one of claims 11 to 30 and a pharmaceutically acceptable carrier or diluent.
37. A method for the treatment or prevention of diseases of the central nervous system (excluding those involving CNS depressant action), cardiovascular system (excluding 30 hypertension), or of the kidney, or diseases associated with abnormal adrenal gland secretions or in the treatment of hyperglycaemia or peptic ulcer which comprises

- 57 -

administering an effective amount of a compound of formula II

5



II

wherein W is optionally substituted aryl, optionally substituted C₅-C₇ cycloalkyl or -CHR¹R² where R¹ and R² are independently selected from hydrogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₃-C₇ cycloalkyl, optionally substituted aryl, and OR' where R' is optionally substituted aryl, optionally substituted C₃-C₇ cycloalkyl or optionally substituted C₁-C₆ alkyl, provided that of R¹ and R² are not both hydrogen, Z is imino, C₁-C₂ alkylene, -CH₂NH- or -CH₂CH₂NH-, X is O or S, and Y is optionally substituted C₂-C₃ alkylene, provided that W is not OR' when Z is imino or -CH₂NH-, or a pharmaceutically acceptable salt or ester thereof, to a subject in need thereof.


15

38. A method according to claim 38 wherein the disease of the central nervous system is selected from dementia, mood disturbances, degenerative conditions such as stroke or aging, ischaemia, CNS trauma, and neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

20

39. A method of the treatment or prevention of glaucoma comprising administering an effective amount of a compound of formula II

25



II

wherein W is optionally substituted aryl, optionally substituted C₅-C₇ cycloalkyl or -CHR¹R² where R¹ and R² are independently selected from hydrogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₃-C₇ cycloalkyl, optionally substituted aryl, and OR' where R' is optionally substituted aryl, optionally substituted C₃-C₇ cycloalkyl or optionally

- 58 -


substituted C₁-C₆ alkyl, provided that of R¹ and R² are not both hydrogen, Z is imino, C₁-C₂ alkylene, -CH₂NH- or -CH₂CH₂NH-, X is O or S, and Y is optionally substituted C₂-C₃ alkylene, provided that W is not OR' when Z is imino or -CH₂NH-; and

5 with the further provisos that

- a) when Y is CH₂CH₂, X is O and Z is imino then
- (i) if W is CHR¹R² and R¹ is H then R² is not selected from phenyl; phenyl substituted with methoxy, Br, Cl, F or trifluoromethyl; or 3-nitrophenyl; 3- or 4-methylphenyl; 2- or 4-bromomethyl phenyl; 2- or 4-chloromethylphenyl; or 2,3- or 10 2,6-dimethylphenyl; and
- (ii) if W is CHR¹R² and R¹ is CH₃ or cyclopropyl then R¹ is not phenyl or phenyl substituted with alkyl, halomethyl, fluoro or trifluoromethyl; and
- b) when Y is (CH₂)₂₋₄, X is O or S, Z is imino and W is CHR¹R², then
- (i) if R¹ is CF₃, CF₂CF₃ or CF₂CF₂CF₃ then R² is not alkyl, optionally substituted 15 cycloalkyl or optionally substituted aryl, and
- (ii) if R¹ is optionally substituted cyclopropyl, R² is not H, alkyl or optionally substituted cyclopropyl;

or a pharmaceutically acceptable ester or salt thereof, to a subject in need thereof.

20 40. Use of a compound of formula II



25

wherein W is optionally substituted aryl, optionally substituted C₅-C₇ cycloalkyl or -CHR¹R² where R¹ and R² are independently selected from hydrogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₃-C₇ cycloalkyl, optionally substituted aryl, and OR' where R' is optionally substituted aryl, optionally substituted C₃-C₇ cycloalkyl or optionally

30 substituted C₁-C₆ alkyl, provided that of R¹ and R² are not both hydrogen, Z is imino, C₁-C₂ alkylene, -CH₂NH- or -CH₂CH₂NH-, X is O or S, and Y is optionally substituted C₂-C₃ alkylene, provided that W is not OR' when Z is imino or -CH₂NH-, or a pharmaceutically


- 59 -

acceptable salt or ester thereof, in the manufacture of a medicament for the prevention or treatment of diseases of the central nervous system (excluding those involving CNS depressant action), cardiovascular system (excluding hypertension), or of the kidney, or diseases associated with abnormal adrenal gland secretions or in the treatment of
5 hyperglycaemia or peptic ulcer.

41 Use according to claim 40 wherein the disease of the central nervous system is selected from dementia, mood disturbances, degenerative conditions such as stroke or aging, ischaemia, CNS trauma, and neurodegenerative diseases such as Alzheimer's
10 disease and Parkinson's disease.

42. Use of a compound of formula II

15



wherein W is optionally substituted aryl, optionally substituted C₃-C₇ cycloalkyl or -CHR¹R² where R¹ and R² are independently selected from hydrogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₃-C₇ cycloalkyl, optionally substituted aryl, and OR' where R' is optionally substituted aryl, optionally substituted C₃-C₇ cycloalkyl or optionally substituted C₁-C₆ alkyl, provided that of R¹ and R² are not both hydrogen, Z is imino, C₁-C₂ alkylene, -CH₂NH- or -CH₂CH₂NH-, X is O or S, and Y is optionally substituted C₂-C₃ alkylene, provided that W is not OR' when Z is imino or -CH₂NH-; and with the further
25 proviso that

- when Y is CH₂CH₂, X is O and Z is imino then
 - if W is CHR¹R² and R¹ is H then R² is not selected from phenyl; phenyl substituted with methoxy, Br, Cl, F or trifluoromethyl; or 3-nitrophenyl; 3- or 4-methylphenyl; 2- or 4-bromomethyl phenyl; 2- or 4-chloromethylphenyl; or 2,3- or 30 2,6-dimethylphenyl; and
 - if W is CHR¹R² and R¹ is CH₃ or cyclopropyl then R¹ is not phenyl or phenyl substituted with alkyl, halomethyl, fluoro or trifluoromethyl; and
- when Y is (CH₂)₂₋₄, X is O or S, Z is imino and W is CHR¹R², then

- 60 -

- (i) if R¹ is CF₃, CF₂CF₃ or CF₂CF₂CF₃ then R² is not alkyl, optionally substituted cycloalkyl or optionally substituted aryl, and
(ii) if R¹ is optionally substituted cyclopropyl, R² is not H, alkyl or optionally substituted cyclopropyl;
- 5 or a pharmaceutically acceptable ester or salt thereof;

in the manufacture of a medicament for the prevention or treatment of glaucoma.

43. Use of a compound of any one of claims 11 to 30 in the manufacture of a
10 medicament for the treatment of diseases of the central nervous system, cardiovascular
system, or the kidney, or diseases associated with abnormal adrenal gland secretions, or in
the treatment or prevention of hyperglycaemia, glaucoma, peptic ulcer or in the production
of analgesia.

15 44 Use of a compound of any one of claims 11 to 30 or a pharmaceutically acceptable
salt or ester thereof in the prevention or treatment of diseases of the central nervous
system, cardiovascular system, or the kidney, or diseases associated with abnormal
adrenal gland secretions or in the treatment or prevention of hyperglycaemia, glaucoma,
peptic ulcer or in the production of analgesia.

20

add 7
a
a a b 7
B 2 1